Artelo biosciences to present at the h.c. wainwright 26th annual global investment conference

Solana beach, calif., sept. 04, 2024 (globe newswire) -- artelo biosciences, inc. (nasdaq: artl), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions today announced that gregory d. gorgas, ceo of artelo biosciences, will be participating in the h.c. wainwright 26th annual global investment conference being held september 9-11, 2024 at the lotte new york palace hotel in new york city.
ARTL Ratings Summary
ARTL Quant Ranking